Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)

Sabine Gravelsina; Zaiga Nora‐krukle; Anda Vilmane; Simons Svirskis; Katrine Vecvagare; Angelika Krūmiņa; Modra Murovska

doi:10.3390/biom11081189

Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)

Sabine Gravelsina (Corresponding Author), Zaiga Nora‐krukle, Anda Vilmane, Simons Svirskis, Katrine Vecvagare, Angelika Krūmiņa, Modra Murovska

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

7 Downloads (Pure)

Abstract

Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age‐related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a bi-omarker for ME/CFS.

Original language	English
Article number	1189
Number of pages	9
Journal	Biomolecules
Volume	11
Issue number	8
DOIs	https://doi.org/10.3390/biom11081189
Publication status	Published - 11 Aug 2021

Keywords*

Human activin B
ME/CFS
Visual analogue scale

Field of Science*

3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/biom11081189

Potential of Activin B as a Clinical BiomarkerLicence: CC BY

Cite this

@article{a196a9b5cd1d4967a66d722500efe775,

title = "Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)",

abstract = "Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age‐related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a bi-omarker for ME/CFS.",

keywords = "Human activin B, ME/CFS, Visual analogue scale",

author = "Sabine Gravelsina and Zaiga Nora‐krukle and Anda Vilmane and Simons Svirskis and Katrine Vecvagare and Angelika Krūmiņa and Modra Murovska",

note = "Funding Information: This research was funded by the Latvian Science Council?s Fundamental and Applied Research project, grant number LZP?2019/1?0380. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = aug,

day = "11",

doi = "10.3390/biom11081189",

language = "English",

volume = "11",

journal = "Biomolecules",

issn = "2218-273X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

TY - JOUR

T1 - Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)

AU - Gravelsina, Sabine

AU - Nora‐krukle, Zaiga

AU - Vilmane, Anda

AU - Svirskis, Simons

AU - Vecvagare, Katrine

AU - Krūmiņa, Angelika

AU - Murovska, Modra

N1 - Funding Information: This research was funded by the Latvian Science Council?s Fundamental and Applied Research project, grant number LZP?2019/1?0380. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/8/11

Y1 - 2021/8/11

N2 - Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age‐related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a bi-omarker for ME/CFS.

AB - Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age‐related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a bi-omarker for ME/CFS.

KW - Human activin B

KW - ME/CFS

KW - Visual analogue scale

UR - http://www.scopus.com/inward/record.url?scp=85112184644&partnerID=8YFLogxK

U2 - 10.3390/biom11081189

DO - 10.3390/biom11081189

M3 - Article

C2 - 34439855

AN - SCOPUS:85112184644

SN - 2218-273X

VL - 11

JO - Biomolecules

JF - Biomolecules

IS - 8

M1 - 1189

ER -

Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)

Abstract

Keywords*

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Fingerprint

Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome

Cite this

Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)

Abstract

Keywords*

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Fingerprint

Datasets

Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome

Cite this